Tango Therapeutics approves strategic reprioritization of research and development activities
TNGX•Tango Therapeutics approved a reprioritization of its research and development activities and intends to reduce its workforce by approximately 14%, with most cuts in research. The company plans to stop certain preclinical and research activities and focus on PRMT5 programs, vopimetostat and TNG456.
1. Research focus shifts
Tango Therapeutics approved a strategic reprioritization of its research and development activities and intends to reduce its overall workforce by approximately 14%, with most of the headcount reductions coming from its research group. The company intends to stop certain preclinical and research activities to focus on translational work and its PRMT5 programs, including vopimetostat and TNG456.
